The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Meet Naval Daver, MD, a professor and director of the Leukemia Molecular Laboratory in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.
In this SOHO Insider interview from the 2026 AACR Annual Meeting, Roy Jensen, MD, vice chancellor and director of the University of Kansas Cancer Center (KU Cancer Center), discusses point-of-care CAR-T manufacturing and the regulatory challenges associated with the process.
In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin,
The US Food and Drug Administration (FDA) has approved ruxolitinib (Jakafi XR) extended-release tablets for adults with intermediate or high-risk myelofibrosis and adults with polycythemia vera who did not respond well to hydroxyurea. It also includes patients ages 12 years and older with steroid-refractory acute or chronic graft-versus-host disease.
In its second year, the Society of Hematologic Oncology (SOHO) will host its virtual SOHO Breakthroughs in Blood Cancers (SBBC) meeting, chaired by Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center. This global event will be held from 8:00 am to 4:40 pm CDT on Thursday, November 12, 2026.
To access the SOHO Career Center click the following link.
